WO1993020822A1 - Compositions of platelet activating factor antagonists and methods of treating interleukin-2 induced lung injury therewith - Google Patents
Compositions of platelet activating factor antagonists and methods of treating interleukin-2 induced lung injury therewith Download PDFInfo
- Publication number
- WO1993020822A1 WO1993020822A1 PCT/US1993/003347 US9303347W WO9320822A1 WO 1993020822 A1 WO1993020822 A1 WO 1993020822A1 US 9303347 W US9303347 W US 9303347W WO 9320822 A1 WO9320822 A1 WO 9320822A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- platelet
- activating factor
- factor antagonist
- composition according
- thieno
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Abstract
Invented is a method of treating Interleukin-2 induced lung injury in a mammal, including human, which comprises administering to such mammal an effective amount of a platelet-activating factor antagonist.
Description
"Compositions of Platelet Activating Factor Antagonists and Methods of Treating Interleukin-2 Induced Lung Injury Therewith"
This invention relates to a method of treating interleukin-2 induced lung injury in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a platelet-activating factor antagonist.
Background of the Invention
Human recombinant Interleukin-2 (IL-2) has been shown to mediate tumor regression in animals
(Ettinghausen, S.E. et al. Cancer Res. 46:2784-2792
(1987)) and Humans (Rosenberg, S.A. et al. N. Eng. J.
Med. 313:1485 (1985)) and is currently under
investigation as a new treatment modality for patients with advanced metastatic cancer (Rosenberg, S.A. et al. N. Eng. J. Med. 316:889 (1987)). The systemic use of IL-2 has, however, also been associated with disorders such as, microvascular injury and pulmonary adema (Clausner, F.L. et al. J. Appl.
Physiol. 64:1030-1037 (1988) and Rosenstein, M. J.
Immunol. 137:1735-1742 (1986)) (hereinafter "lung
injury"). The acute pulmonary toxicity associated with IL-2 infusion has been proposed to result from
Lymphocyte activation (Anderson, T.D. et al. Lab.
Invest. 59:598-612 (1988), Damle, N.K. et al. J.
Immunol. 142:2660-2659 (1989) and Damle, U.K. et al. J. Immunol. 138:1779-1785 (1987)), the production of
inflammatory mediators such as interleukin-1 (IL-1)
Numerof, R.P. et al. J. Immunol 141:4250-4257 (1988)) or tumor Necrosis Factor-α (Helsop, H.E. et al. Blood
74: 1374-1380 (1989) and Nedwin, G.E. et al. J. Immunol. 135:2492-2496 (1985) and from the IL-2 induced
activation of Humoral systems such as the complement cascade (Thijs, L.G. J. Immunol. 144:2419-2424 (1990)). The actual mechanism(s) of IL-2-induced lung injury is presently unknown.
PAF (platelet activating factor) is phospholipid acetyl-glyceryl-ether-phosphoryl-choline (AGEPC) which is known as a potent lipid mediator released by animal and human proinflammatory cells. These cells include mainly basophilic and neutrophilic granulocytes,
macrophages (from blood and tissue) and thrombocytes which are involved in inflammatory reactions.
Compounds which inhibit PAF are reported to be of potential value in the treatment, of a variety of conditions including allergic, inflammatory and hypersecretory
conditions such as asthma, arthritis, rhinitis, bronchitis and urticaria, the treatment of circulatory shock, gastric, ulceration, psoriasis and cardiovascular conditions, including angina, thrombosis and stroke, (WO 91/17162 published November 14, 1991).
Presently, PAF inhibitors are not known as having utility in treating IL-2-induced lung injuries.
Summary of the Invention
This invention relates to a method of treating interleukin-2 induced lung injury in a mammal, including a human, in need thereof which comprises administering to such mammal an. effective amount of a platelet-activating factor antagonist.
Detailed Description of the Invention Illustrative of compounds that have PAF activity are the following comopunds
A)
B)
C)
which is tetrahydro-4,7,8,10 methyl-(chloro-2phenyl) -6 [ (dimethoxy-3, 4phenyl) thio] methylthiocarbonyl-9 pyrido [4',3'-4,5] thieno [3,2-f]triazolo-1,2,4[4,3-a] diazepine-1,4 (hereinafter compound C) and which is disclosed in U.S. Patent No. 5,049,559 as a specific platelet-activating factor antagonist.
D)
By the term "treating" as used herein is meant prophylactic or therapeutic therapy.
By the term "U" as used herein is meant a unit of IL-2 activity as specified by the manufacturer (i.e. Hoffman-La Rocke, Nutley, NJ).
It has now been discovered that compounds which are antagonists of platelet-activating factor are useful in treating interleukin-2 (IL-2) induced lung injury.
Compound C was tested for its in vivo potency in treating IL-2 induced lung injury. To perform the experiments recombinant human IL-2 (obtained from
Hoffman-La Roche, Nutley, NJ) was reconstituted before use with 1 ml of 0.9% NaCl per 106U IL-2. A 105 U dose of IL-2 was prepared by diluting the above 106 U dose 10 times. Compound C was solubilized in 64% DMSO, in 0.9% NaCl to reach a concentration of 5 mg/ml. Male SpragueDawley Rats (obtained from Charles River, Wilmington, MA) were housed in groups of three in standard cages, and kept with food and water ad libitum in a
temperature controlled room (22°C) on a 12 hour
dark/light cycle, until surgery.
Following anesthesia with pentobarbital (30 mg/kg, i.p.) the animals were randomly assorted into three groups.
Group I. IL-2 at 105 U/kg (n=14) (as used herein the term "n" means the number of rats),
106 U/kg (n=18) or vehicle (n=12) was infused intravenously for one hour
(syringe infusion pump 22, Harvard apparatus, South Natick, MA).
Group II. IL-2 at 106 U/kg was administered by
bolus injection followed by IL-2 at 106
U/kg intravenous injection for one hour (n=6), vehicle treated animals served as controls (n=6).
Group III. IL-2 at 106 U/kg was administered by intravenous injection for 1 hour, 30 minutes after pretreatment with compound C (10 mg/kg, I.P.) (n=6) or compound C vehicle (n=6).
At the end of the experimental period the left lung was removed and immediately frozen on dry ice until assayed. When defrosted the lung was weighed to
determine wet weight. Dry weight was determined after the lung was dried at 80°C for 36 hours, and the
pulmonary water content was calculated by subtracting the lung dry weight from the wet lung weight.
The wet (485 ±4 mg), dry (92 ±4 mg) and wet-dry (pulmonary water content, 393 ±4 mg) lung weight did not differ among the control (vehicle treated) groups. IL-2 increased wet (P< 0.05), dry and wet-dry (P<0.01) lung weight in a dose-dependent manner. The wet-dry/dry ratio however remained unchanged. Pretreatment with compound C prevented the responses (P<0.05).
The results of the above experiments clearly demonstrates the therapeutic utility of platelet-activating factor antagonist on treating IL-2 induced lung injury.
This invention discloses platelet-activating factor antagonist and pharmaceutically acceptable salts or hydrates or solvates thereof as being useful for treating IL-2 induced lung injury in mammals, including humans.
A platelet-activating factor antagonist or a pharmaceutically acceptable salt or hydrate or solvate thereof can be administered to a subject in a
conventional dosage form prepared by combining a platelet-activating factor antagonist or a
pharmaceutically acceptable salt or hydrate or solvate thereof, with a conventional pharmaceutically acceptable carrier or diluent according to known techniques.
It will be recognized by one of skill in the art that the form and character of the pharmaceutically acceptable carrier or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well-known
variables. A platelet-activating factor antagonist or a pharmaceutically acceptable salt or hydrate or solvate thereof is administered to a mammal, including a human, in an amount sufficient to prevent or alleviate IL-2 induced lung injury.
The route of administration of the platelet-activating factor antagonist is not critical but is usually oral or parenteral, perferably oral.
The term parenteral as used herein includes
intravenous, intramuscular, subcutaneous, intranasal, intrarectal, transdermal, intravaginal or
intraperitoneal administration. The subcutaneous and intramuscular forms of parenteral administration are generally preferred. The daily parenteral dosage regimen will preferably be from about 0.01 mg/kg to about 20 mg/kg of total body weight, most preferably, from about 0.1 mg/kg to about 5 mg/kg. Preferably, each parenteral dosage unit will contain the active
ingredient in an amount of from about 2 mg to about 150 mg.
The platelet-activating factor antagonist which are active when given orally can be formulated as liquids, for example, syrups, suspensions or emulsions, tablets, capsules and lozenges.
A liquid formulation will generally consist of a suspension or solution of the compound or
pharmaceutically acceptable salt in a suitable liquid carrier (s) for example, ethanol, glycerine, non-aqueous
solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavoring or coloring agent.
A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier (s) routinely used for preparing solid formulations .
Examples of such carriers include magnesium stearate, starch, lactose, sucrose and cellulose.
A composition in the form of a capsule can be prepared using routine encapsulation procedures. For example, pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable
pharmaceutical carrier (s), for example aqueous gums;
celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
The daily oral dosage regimen will preferably be from about 0.01 mg/kg to about 20 mg/kg of total body weight. Preferably each oral dosage unit will contain the active ingredient in an amount of from about 2 mg to about 150 mg.
While it is possible for an activate ingredient to be administered alone, it is preferable to present it as a pharmaceutical formulation.
It will be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages of a platelet-activating factor antagonist or a pharmaceutically acceptable salt or hydrate or solvate thereof will be determined by the nature and extent of the exact condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.w., the number of doses of a platelet-
activating factor antagonist or a pharmaceutically acceptable salt or hydrate or solvate thereof given per day and duration of therapy, can be ascertained by those skilled in the art using conventional course of
treatment determination tests.
Without further elaboration, it is believed that one skilled in the art can, using the preceding
description, utilize the present invention to its fullest extent. The following examples are, therefore, to be construed as merely illustrative and not a
limitation of the scope of the present invention in any way.
Example 1 - Capsule Composition
A oral dosage form for administering a platelet-activating factor antagonist is produced by filing a standard two piece hard gelatin capsule with the
ingredients in the proportions shown in Table I, below.
Table I
INGREDIENTS AMOUNTS
Compound C 25 mg
Lactose 55 mg
Talc 16 mg
Magnesium Stearate 4 mg
Example 2 - Injectable Parenteral Composition
An injectable form for administering a platelet-activating factor antagonist is produced by stirring
1.5% by weight of Compound C in 10% by volume propylene glycol in water.
Example 3 - Tablet Composition
The sucrose, calcium sulfate dihydrate and a platelet-activating factor antagonist shown in Table II below, are mixed and granulated in the proportions shown
with a 10% gelatin solution. The wet granules are screened, dried, mixed with the starch, talc and stearic acid, screened and compressed into a tablet.
Table II
INGREDIENTS AMOUNTS
Compound C 20 mg
calcium sulfate dihydrate 30 mg
sucrose 4 mg
starch 2 mg
talc 1 mg
stearic acid 0.5 mg
While the above descriptions and examples fully describe the invention and the preferred embodiments thereof, it is understood that the invention is not limited to the particular disclosed embodiments coming within the scope of the following claims.
Claims
1. Use of a platelet-activating factor antagonist in the
manufacture of a medicament for use in treating interleukin-2 induced lung injury in a mammal.
2. A use according to claim 1 wherein the mammal is a human.
3. A use according to claim 2 wherein the platelet-activating factor antagonist is 5-[(2-Chlorophenyl)-3,4-dihydro-10-methyl-3-[(4-morpholmyl) carbonyl]-2H,7H-cyclopenta [4,5] thieno [3,2-f] [1,2.4] triazolo [4,3-a] [1,4] diazepine.
4. A use according to claim 2 wherein the platelet-activating factor antagonist is 3-[4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f] [1,2,4] triazolo-[4,3-a] [1,4]-diazepin-2-yl]-1-(4-morpholinyl)-1-propanon.
5. A use according to claim 2 wherein the platelet-activating factor antagonist is tetrahydro-4,7,8,10 methyl-(chloro-2phenyl)-6[(dimethoxy-3,4phenyl) thio] methylthiocarbonyl-9 pyrido[4',3'-4.5] thieno [3,2-f] triazolo-1,2-4 [4,3-a] diazepine-1,4.
6. A use according to claim 2 wherein the platelet-activating factor antagonist is (+) N-(3-benzoylphenyl)3-(3 pyridyl)-1H, 3H pyrrolo [1,2-c] thiazole-7 carboxamide.
7. A use according to claim 2 wherein the platelet-activating . factor antagonist is administered orally.
8. A use according to claim 7 wherein from about 0.01 mg/kg to about 20 mg/kg of the platelet-activating factor antagonist is administered per day.
9. A use according to claim 2 wherein the platelet-activating factor antagonist is administered parenterally.
10. A use according to claim 9 wherein from about 0.01 mg to about 20 mg/kg of the platelet-activating factor antagonist is administered per day.
11. A pharmaceutical composition, for use in the treatment of interleukin-2 induced lung injury in a mammal comprising a platelet-activating factor antagonist, and a pharmaceutically acceptable carrier.
12. A composition according to claim 11 wherein the mammal is a human.
13. A composition according to claim 12 wherein the platelet-activating factor antagonist is 5-[(2-Chlorophenyl)-3,4-dihydro-10-methyl-3-[(4-morpholinyl) carbonyl]-2H,7H-cyclopenta [4,5]thieno[3,2-f] [1,2,4] triazolo [4.3-a] [1,4] diazepine.
14. A composition according to claim 12 wherein the platelet-activating factor antagonist is 3-[4-(2-chIorophenyl)-9-methyl-6H-thieno [3,2-f] [1-2-4] triazolo-[4,3-a] [1,4]-diazepin-2-yl]-1-(4-morpholinyl)-1-propanon.
15. A composition according to claim 12 wherein the plateletactivating factor antagonist is tetrahydro-4,7,8,10 methyl-(chloro-2phenyl)-6[(dimethoxy-3-4phenyl) thio] methylthiocarbonyl-9 pyrido [4',3'-4,5] thieno [3,2-f] triazolo-1,2-4 [4,3-a] diazepine-1,4.
16. A composition according to claim 12 wherein the plateletactivating factor antagonist is (+) N-(3-benzoyIphenyl)3-(3 pyridyl)-1H, 3H pyrrolo [1,2-c] thiazole-7 carboxamide.
17. A composition according to claim 12 wherein the plateletactivating factor antagonist is administered orally.
18. A composition according to claim 17 wherein from about 0.01 mg/kg to about 20 mg/kg of the platelet-activating factor antagonist is administered per day.
19. A composition according to claim 12 wherein the platelet-activating factor antagonist is administered parenterally.
20. A composition according to claim 19 wherein from about 0.01 mg to about 20 mg/kg of the platelet-activating factor antagonist is administered per day.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP93912168A EP0634933A1 (en) | 1992-04-08 | 1993-04-08 | Compositions of platelet activating factor antagonists and methods of treating interleukin-2 induced lung injury therewith |
| JP5518492A JPH07505885A (en) | 1992-04-08 | 1993-04-08 | Platelet activating factor antagonist composition and method for treating interleukin-2-induced lung injury therewith |
| KR1019940703602A KR950700740A (en) | 1992-04-08 | 1994-10-07 | Compositions of Platelet Activating Factor Antagonists and Methods of Treating Interleukin-2 Induced Lung Injury Therewith |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929207645A GB9207645D0 (en) | 1992-04-08 | 1992-04-08 | Methods |
| GB9207645.4 | 1992-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1993020822A1 true WO1993020822A1 (en) | 1993-10-28 |
Family
ID=10713637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1993/003347 WO1993020822A1 (en) | 1992-04-08 | 1993-04-08 | Compositions of platelet activating factor antagonists and methods of treating interleukin-2 induced lung injury therewith |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0634933A1 (en) |
| JP (1) | JPH07505885A (en) |
| KR (1) | KR950700740A (en) |
| AU (1) | AU4281993A (en) |
| CA (1) | CA2133754A1 (en) |
| GB (1) | GB9207645D0 (en) |
| WO (1) | WO1993020822A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4783472A (en) * | 1986-07-04 | 1988-11-08 | Rhone-Poulenc Sante | 1H,3H-pyrrol[1,2-c]thiazole derivatives and pharmaceutical compositions containing them |
| US5049559A (en) * | 1989-05-13 | 1991-09-17 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Thieno-triazolo-diazepine derivatives useful as anti-ischemic agents |
| US5082839A (en) * | 1985-01-25 | 1992-01-21 | Boehringer Ingelheim Gmbh | Thieno-triazolo-1,4-diazepino-2-carboxylic acid amides |
-
1992
- 1992-04-08 GB GB929207645A patent/GB9207645D0/en active Pending
-
1993
- 1993-04-08 JP JP5518492A patent/JPH07505885A/en active Pending
- 1993-04-08 WO PCT/US1993/003347 patent/WO1993020822A1/en not_active Application Discontinuation
- 1993-04-08 EP EP93912168A patent/EP0634933A1/en not_active Withdrawn
- 1993-04-08 CA CA002133754A patent/CA2133754A1/en not_active Abandoned
- 1993-04-08 AU AU42819/93A patent/AU4281993A/en not_active Abandoned
-
1994
- 1994-10-07 KR KR1019940703602A patent/KR950700740A/en not_active Application Discontinuation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5082839A (en) * | 1985-01-25 | 1992-01-21 | Boehringer Ingelheim Gmbh | Thieno-triazolo-1,4-diazepino-2-carboxylic acid amides |
| US4783472A (en) * | 1986-07-04 | 1988-11-08 | Rhone-Poulenc Sante | 1H,3H-pyrrol[1,2-c]thiazole derivatives and pharmaceutical compositions containing them |
| US5049559A (en) * | 1989-05-13 | 1991-09-17 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Thieno-triazolo-diazepine derivatives useful as anti-ischemic agents |
Non-Patent Citations (6)
| Title |
|---|
| CHEMICAL ABSTRACTS, Vol. 112(15), No. 1321148v, 1990, CHANG et al. * |
| CHEMICAL ABSTRACTS, Vol. 114(1), No. 315d, 1990, GULBENKIAN et al. * |
| CHEMICAL ABSTRACTS, Vol. 115(7), No. 69447m, 1991, HELLEWELL et al. * |
| CHEMICAL ABSTRACTS, Vol. 116(13), No. 1205756, 1991, HEUER. * |
| CHEMICAL ABSTRACTS, Vol. 116(21), No. 212769w, 1992, TAVARES DE LIMA et al. * |
| CHEMICAL ABSTRACTS, Vol. 116(9), No. 7610y, 1991, HEUER. * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR950700740A (en) | 1995-02-20 |
| EP0634933A1 (en) | 1995-01-25 |
| AU4281993A (en) | 1993-11-18 |
| GB9207645D0 (en) | 1992-05-27 |
| CA2133754A1 (en) | 1993-10-28 |
| JPH07505885A (en) | 1995-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20050020665A1 (en) | Pharmaceutical composition for treating multiple sclerosis | |
| US20030109543A1 (en) | Novel combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination | |
| CA2450777A1 (en) | Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia | |
| Casals‐Stenzel et al. | Triazolodiazepines: dissociation of their Paf (platelet activating factor) antagonistic and CNS activity | |
| CZ20031660A3 (en) | Pharmaceutical formulation containing aspirin | |
| CN101198334A (en) | Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders | |
| KR20070085470A (en) | S-mirtazapine for the treatment of hot flush | |
| IE851821L (en) | Anticoagulant composition | |
| US4393063A (en) | Treatment for gastric lesions | |
| EP0295836B1 (en) | Use of dioxopiperidine derivatives for the manufacture of topical medicaments as analgesics | |
| EP0005015A1 (en) | Use of a xanthine derivate in the manufacture of a medicament | |
| JP2009102399A (en) | Composition containing adenosine a1 receptor antagonist and method, for restoring diuretic and renal function | |
| WO1993020822A1 (en) | Compositions of platelet activating factor antagonists and methods of treating interleukin-2 induced lung injury therewith | |
| JPH0655673B2 (en) | PAF antagonist-antihistamine combinations and methods of use | |
| EP0081006A1 (en) | Pharmaceutical compositions comprising 7,8-dihydroxy-1(hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine derivatives and a beta-adrenergic blocking compound | |
| HRP20010429A2 (en) | Formulation with an improved therapeutic range, containing nucleotide synthesis inhibitors | |
| WO2011149110A1 (en) | Novel composition for the prevention and/or treatment of thromboembolism | |
| CA2493384A1 (en) | Medicinal composition for treating arteriosclerosis | |
| Young et al. | Pharmacokinetics and toxicity of 5-day continuous infusion of vinblastine | |
| GB2105192A (en) | Composition for use in treating atherosclerosis | |
| KR20200055117A (en) | Pharmaceutical composition for prevention or treatment of cancer, including PI3 kinase inhibitor and cytotoxic anticancer agent | |
| JPH0680011B2 (en) | Medicine for the prevention and treatment of thrombosis | |
| JPH0232020A (en) | Method and drug for suppressing manifestation of tolerance in morphine analgestic treatment | |
| SE443716B (en) | SETTING TO PREPARE A PHARMACEUTICAL PREPARATION FOR INHIBITING BLOOD SPOT SEGREGATION CONTAINING PROSTACYCLINE OR DIHYDROPROSTACYCLINE AND A PHOSPHODIESTERATION INHIBITOR | |
| RU2275905C2 (en) | Pharmaceutical compositions against headache, migraine, sickness, and retch |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP KR NZ US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 252805 Country of ref document: NZ |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2133754 Country of ref document: CA |
|
| ENP | Entry into the national phase |
Ref document number: 1994 313312 Country of ref document: US Date of ref document: 19941006 Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1993912168 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1993912168 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1993912168 Country of ref document: EP |